AMRS Stock Price
AMRS RSI Chart
AMRS Valuation
AMRS Price/Sales (Trailing)
AMRS Profitability
AMRS Fundamentals
AMRS Revenue
AMRS Earnings
Price Action
Last 7 days
-63.5%
Last 30 days
-95%
Last 90 days
-91.4%
Trailing 12 Months
-98.6%
AMRS Financial Health
AMRS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for AMRS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-06-02 | Kieftenbeld Hermanus | sold | -19,949 | 0.95 | -20,999 | chief financial officer |
2023-04-19 | Qi Lisa | acquired | - | - | 10,537 | - |
2023-04-19 | Panchadsaram Ryan | acquired | - | - | 9,667 | - |
2023-04-19 | DOERR L JOHN | acquired | - | - | 11,600 | - |
2023-04-19 | MCCANN JAMES F | acquired | - | - | 13,437 | - |
2023-04-05 | ALVAREZ EDUARDO | sold | -284,305 | 1.2288 | -231,368 | chief operating officer |
2023-04-04 | ALVAREZ EDUARDO | acquired | - | - | 492,000 | chief operating officer |
2023-01-20 | Qi Lisa | acquired | - | - | 7,532 | - |
2023-01-20 | Panchadsaram Ryan | acquired | - | - | 7,947 | - |
2023-01-20 | DOERR L JOHN | acquired | - | - | 8,292 | - |
Which funds bought or sold AMRS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -54.64 | -144,129 | 75,449 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -5.49 | -115,650 | 291,229 | -% |
2023-08-17 | SILVERBACK ASSET MANAGEMENT LLC | new | - | 206,000 | 206,000 | 0.03% |
2023-08-16 | GTS SECURITIES LLC | new | - | 11,928 | 11,928 | -% |
2023-08-16 | Nuveen Asset Management, LLC | unchanged | - | -91,118 | 283,882 | -% |
2023-08-15 | BENJAMIN EDWARDS INC | unchanged | - | - | - | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 126 | 204,466 | 490,725 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | reduced | -91.57 | -3,778,000 | 257,000 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 67.12 | 67,103 | 319,678 | -% |
2023-08-15 | Gordian Capital Singapore Pte Ltd | sold off | -100 | -7,000 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Amyris
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 20, 2023 | foris ventures, llc | 30.2% | 122,034,555 | SC 13D/A | |
| Aug 10, 2023 | foris ventures, llc | 29.9% | 120,499,897 | SC 13D/A | |
| Aug 03, 2023 | foris ventures, llc | 29.9% | 120,480,436 | SC 13D/A | |
| Jun 30, 2023 | foris ventures, llc | 29.9% | 120,385,914 | SC 13D/A | |
| Jun 09, 2023 | foris ventures, llc | 29.9% | 120,319,193 | SC 13D/A | |
| Jun 07, 2023 | dsm international b.v. | - | 0 | SC 13D/A | |
| May 24, 2023 | foris ventures, llc | 29.9% | 120,177,411 | SC 13D/A | |
| Mar 17, 2023 | foris ventures, llc | 30.1% | 119,877,165 | SC 13D/A | |
| Feb 14, 2023 | cvi investments, inc. | 4.9% | 18,163,117 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 5.84% | 21,211,189 | SC 13G/A |
Recent SEC filings of Amyris
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 20, 2023 | 3 | Insider Trading | |
| Sep 20, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Sep 19, 2023 | 8-K | Current Report | |
| Sep 08, 2023 | 25-NSE | 25-NSE | |
| Aug 31, 2023 | 8-K | Current Report | |
| Aug 17, 2023 | 3 | Insider Trading | |
| Aug 17, 2023 | 3 | Insider Trading | |
| Aug 15, 2023 | 8-K | Current Report | |
| Aug 11, 2023 | 8-K | Current Report | |
| Aug 10, 2023 | 8-K | Current Report |
Peers (Alternatives to Amyris)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LYB | 31.0B | 43.0B | -2.41% | 27.87% | 14.66 | 0.72 | -19.65% | -61.23% |
IFF | 17.5B | 11.9B | 2.30% | -30.31% | -7.96 | 1.47 | -6.11% | -441.15% |
WLK | 15.4B | 13.9B | -6.90% | 40.29% | 11.56 | 1.11 | -8.20% | -53.46% |
RPM | 12.1B | 7.3B | -5.83% | 8.92% | 25.29 | 1.67 | 8.18% | -2.60% |
PPG | - | 17.9B | -7.28% | 13.84% | - | - | 1.96% | 21.57% |
| MID-CAP | ||||||||
AXTA | - | 5.1B | -4.22% | 12.94% | - | - | 9.03% | 9.70% |
OLN | 5.9B | 7.8B | -16.23% | 4.63% | 7.32 | 0.76 | -20.33% | -46.41% |
NEU | 4.4B | 2.8B | -0.14% | 53.03% | 12.43 | 1.58 | 7.02% | 79.95% |
SXT | 2.6B | 1.5B | 3.49% | -17.17% | 19.26 | 1.76 | 2.92% | -2.93% |
| SMALL-CAP | ||||||||
FF | 319.0M | 395.4M | -0.13% | 21.63% | 7.61 | 0.81 | 6.42% | 107.62% |
WLKP | - | 1.4B | -3.36% | -0.27% | - | - | -5.70% | -3.36% |
AMRS | 29.3M | 268.2M | -95.00% | -98.59% | -0.05 | 0.11 | 20.46% | -592.58% |
Amyris News
Returns for AMRS
Cumulative Returns on AMRS
-48.6%
10-Year Cumulative Returns
-50.0%
7-Year Cumulative Returns
-62.3%
5-Year Cumulative Returns
-75.8%
3-Year Cumulative Returns
Risks for AMRS
What is the probability of a big loss on AMRS?
100%
Probability that Amyris stock will be more than 20% underwater in next one year
96.5%
Probability that Amyris stock will be more than 30% underwater in next one year.
96.5%
Probability that Amyris stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does AMRS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Amyris was unfortunately bought at previous high price.
Drawdowns
Financials for Amyris
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Revenue | -0.6% | 268,221,000 | 269,847,000 | 258,821,000 | 235,558,000 | 222,667,000 | 341,817,000 | 356,785,000 | 343,177,000 | 320,866,000 | 173,137,000 | 133,929,000 | 134,624,000 | 167,313,000 | 152,557,000 | 128,392,000 | 107,754,000 | 60,119,000 | 63,604,000 | 127,821,000 | 137,703,000 | 148,324,000 |
| Costs and Expenses | 7.1% | 898,173,000 | 838,830,000 | 803,838,000 | 719,242,000 | 617,799,000 | 519,443,000 | 408,532,000 | 356,161,000 | 319,542,000 | 296,559,000 | 286,252,000 | 276,939,000 | 271,578,000 | 274,447,000 | 267,063,000 | 246,294,000 | 222,746,000 | 200,187,000 | 182,799,000 | 178,817,000 | 184,637,000 |
| S&GA Expenses | -2.2% | 482,583,000 | 493,629,000 | 453,126,000 | 399,052,000 | 326,805,000 | 257,811,000 | 199,130,000 | 166,816,000 | 142,979,000 | 137,071,000 | 134,968,000 | 129,988,000 | 130,347,000 | 126,586,000 | 118,565,000 | 112,463,000 | 101,055,000 | 90,902,000 | 84,393,000 | 72,608,000 | 69,103,000 |
| R&D Expenses | 0.4% | 110,622,000 | 110,215,000 | 105,958,000 | 101,002,000 | 97,315,000 | 94,289,000 | 88,968,000 | 83,341,000 | 77,882,000 | 71,676,000 | 67,655,000 | 68,490,000 | 70,747,000 | 71,460,000 | 74,876,000 | 72,289,000 | 68,736,000 | 68,722,000 | 63,360,000 | 62,100,000 | 60,680,000 |
| EBITDA | -16.5% | -584,044,000 | -501,519,000 | -313,100,000 | -182,997,000 | -62,647,000 | -244,733,000 | -391,486,000 | -376,422,000 | -486,121,000 | -274,276,000 | -232,067,000 | -260,797,000 | -196,649,000 | -178,892,000 | - | - | - | - | - | - | - |
| EBITDA Margin | -17.2% | -2.18 | -1.86 | -1.21 | -0.78 | -0.28 | -0.72 | -1.10 | -1.10 | -1.52 | -1.58 | -1.73 | -1.94 | -1.18 | -1.17 | - | - | - | - | - | - | - |
| Interest Expenses | 31.2% | 32,453,000 | 24,733,000 | 27,604,000 | 25,636,000 | 25,055,000 | 25,605,000 | 21,061,000 | 23,367,000 | 38,762,000 | 47,951,000 | 55,804,000 | 66,034,000 | 61,133,000 | 58,665,000 | 58,573,000 | 50,896,000 | 45,259,000 | 42,703,000 | 36,600,000 | 35,153,000 | 34,876,000 |
| Earnings Before Taxes | -17.1% | -630,997,000 | -538,625,000 | -351,102,000 | -218,064,000 | -92,187,000 | -272,311,000 | -415,396,000 | -402,317,000 | -526,900,000 | -323,850,000 | -295,060,000 | -333,084,000 | -263,233,000 | -242,138,000 | -211,958,000 | -227,382,000 | -203,676,000 | -230,235,000 | -260,081,000 | -219,807,000 | -204,495,000 |
| EBT Margin | -17.9% | -2.35 | -2.00 | -1.36 | -0.93 | -0.44 | -0.82 | -1.18 | -1.19 | -1.66 | -1.91 | -2.20 | -2.47 | -1.57 | -1.59 | - | - | - | - | - | - | - |
| Net Income | -17.9% | -622,981,000 | -528,510,000 | -343,796,000 | -215,345,000 | -89,951,000 | -270,969,000 | -418,431,000 | -408,643,000 | -532,339,000 | -331,039,000 | -298,189,000 | -334,595,000 | -264,368,000 | -242,767,000 | -212,491,000 | -227,382,000 | -203,676,000 | -230,235,000 | -183,354,000 | -142,762,000 | -127,760,000 |
| Net Income Margin | -18.6% | -2.32 | -1.96 | -1.32 | -0.90 | -0.39 | -0.79 | -1.17 | -1.19 | -1.67 | -1.91 | -2.24 | -2.50 | -1.58 | -1.59 | - | - | - | - | - | - | - |
| Free Cashflow | 11.9% | -463,453,000 | -525,894,000 | -575,187,000 | -511,021,000 | -442,426,000 | -181,333,000 | -49,103,000 | -35,216,000 | -20,727,000 | -175,753,000 | -209,279,000 | -209,008,000 | -166,328,000 | -156,933,000 | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Assets | -17.6% | 680 | 825 | 754 | 789 | 898 | 954 | 542 | 446 | 327 | 223 | 206 | 268 | 167 | 161 | 128 | 123 | 105 | 128 | 123 | 119 | 118 |
| Current Assets | -20.5% | 244 | 306 | 272 | 310 | 471 | 639 | 278 | 349 | 252 | 147 | 131 | 191 | 85.00 | 74.00 | 55.00 | 46.00 | 36.00 | 92.00 | 68.00 | 67.00 | 74.00 |
| Cash Equivalents | -82.5% | 11.00 | 64.00 | 19.00 | 100 | 288 | 488 | 115 | 214 | 144 | 30.00 | 38.00 | 100 | 3.00 | 2.00 | 2.00 | 1.00 | 5.00 | 47.00 | 19.00 | 14.00 | 24.00 |
| Inventory | -2.6% | 109 | 112 | 129 | 99.00 | 82.00 | 75.00 | 72.00 | 54.00 | 48.00 | 43.00 | 37.00 | 33.00 | 31.00 | 28.00 | 16.00 | 14.00 | 8.00 | 10.00 | 6.00 | 7.00 | 5.00 |
| Net PPE | 4.1% | 190 | 182 | 170 | 151 | 125 | 73.00 | 53.00 | 42.00 | 32.00 | 33.00 | 30.00 | 27.00 | 27.00 | 29.00 | 24.00 | 24.00 | 22.00 | 20.00 | 17.00 | 15.00 | 13.00 |
| Goodwill | -64.6% | 50.00 | 143 | 127 | 134 | 1.00 | 131 | 129 | 4.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Liabilities | 2.7% | 1,328 | 1,293 | 1,159 | 1,033 | 1,024 | 675 | 596 | 528 | 637 | 390 | 285 | 327 | 343 | 411 | 336 | 298 | 337 | 340 | 323 | 368 | 404 |
| Current Liabilities | 21.6% | 471 | 387 | 309 | 187 | 266 | 270 | 460 | 95.00 | 147 | 163 | 104 | 129 | 192 | 161 | 159 | 190 | 236 | 212 | 154 | 159 | 111 |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 25.00 | 37.00 | 46.00 | 26.00 | 63.00 | 0.00 | 60.00 | - | - | - | - |
| LT Debt, Current | 2.7% | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 25.00 | 1.00 | 56.00 | 55.00 | 31.00 | 43.00 | 77.00 | 45.00 | 65.00 | 79.00 | 129 | 124 | 62.00 | 60.00 | 34.00 |
| LT Debt, Non Current | 0.1% | 676 | 675 | 674 | 673 | 672 | 309 | 12.00 | 14.00 | 14.00 | 26.00 | 26.00 | 24.00 | 12.00 | 48.00 | 20.00 | 10.00 | 43.00 | 43.00 | 44.00 | 44.00 | 62.00 |
| Shareholder's Equity | - | - | - | - | - | - | 246 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Retained Earnings | -7.6% | -3,100 | -2,880 | -2,730 | -2,568 | -2,458 | -2,357 | -2,395 | -2,362 | -2,377 | -2,086 | -2,000 | -2,000 | -1,843 | -1,755 | -1,676 | -1,617 | -1,579 | -1,521 | -1,367 | -1,298 | -1,300 |
| Additional Paid-In Capital | 0.4% | 2,466 | 2,456 | 2,384 | 2,357 | - | 2,657 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shares Outstanding | 1.0% | 369 | 365 | 325 | 321 | 313 | 309 | 301 | 320 | 268 | 245 | 227 | 185 | 155 | 118 | 103 | 93.00 | 78.00 | 77.00 | 56.00 | 55.00 | 51.00 |
| Minority Interest | 24.4% | -9.76 | -12.91 | -13.10 | -6.60 | -3.52 | -0.75 | 2.00 | 6.00 | 6.00 | 5.00 | 4.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Cashflow From Operations | 11.9% | -463 | -525 | -575 | -511 | -442 | -181 | -49.10 | -35.22 | -20.73 | -175 | -209 | -209 | -166 | -156 | -133 | -113 | -121 | -109 | -87.97 | -95.49 | -100 |
| Share Based Compensation | -11.9% | 43.00 | 49.00 | 48.00 | 45.00 | 41.00 | 33.00 | 26.00 | 20.00 | 15.00 | 14.00 | 12.00 | 12.00 | 13.00 | 13.00 | 13.00 | 13.00 | 11.00 | 9.00 | 8.00 | 7.00 | 6.00 |
| Cashflow From Investing | 34.3% | -81.24 | -123 | -142 | -147 | -108 | -64.10 | -43.74 | -12.96 | -14.23 | -12.78 | -13.69 | -12.62 | -11.07 | -13.08 | -15.12 | -14.06 | -13.93 | -12.47 | 43.00 | 48.00 | 50.00 |
| Cashflow From Financing | 16.3% | 269 | 231 | 626 | 550 | 698 | 702 | 173 | 166 | 180 | 223 | 260 | 320 | 175 | 125 | 131 | 113 | 114 | 108 | 45.00 | 55.00 | 75.00 |
AMRS Income Statement
2023-03-31Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Revenue: | ||
| Revenue | $ 56,083 | $ 57,709 |
| Cost and operating expenses: | ||
| Cost of products sold | 51,081 | 48,995 |
| Research and development | 26,765 | 26,358 |
| Sales, general and administrative | 95,870 | 106,916 |
| Change in fair value of acquisition-related contingent consideration | (28,503) | 0 |
| Restructuring | 1,013 | 0 |
| Impairment | 95,386 | 0 |
| Total cost and operating expenses | 241,612 | 182,269 |
| Loss from operations | (185,529) | (124,560) |
| Other income (expense): | ||
| Interest expense | (12,983) | (5,263) |
| Gain from change in fair value of derivative instruments | 1,263 | 1,815 |
| (Loss) gain from change in fair value of debt | (4,854) | 20,796 |
| Other expense, net | (533) | (3,052) |
| Total other (expense) income, net | (17,107) | 14,296 |
| Loss before income taxes and loss from investment in affiliate | (202,636) | (110,264) |
| Benefit from income taxes | 860 | 820 |
| Loss from investment in affiliate | 0 | (789) |
| Net loss | (201,776) | (110,233) |
| Loss attributable to noncontrolling interest | 8,434 | 2,928 |
| Net loss attributable to Amyris, Inc. common stockholders | $ (193,342) | $ (107,305) |
| Earnings Per Share [Abstract] | ||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | $ (0.53) | $ (0.34) |
| Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares) | 365,603,738 | 312,896,452 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | $ (0.53) | $ (0.37) |
| Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares) | 365,603,738 | 323,711,682 |
| Renewable Products | ||
| Revenue: | ||
| Revenue | $ 40,224 | $ 43,465 |
| Licenses and Royalties | ||
| Revenue: | ||
| Revenue | 9,482 | 9,313 |
| Collaborations, Grants and Other | ||
| Revenue: | ||
| Revenue | $ 6,377 | $ 4,931 |
AMRS Balance Sheet
2023-03-31Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 11,245 | $ 64,437 |
| Restricted cash | 71 | 71 |
| Accounts receivable, net of allowance of $997 and $995 | 36,842 | 45,775 |
| Accounts receivable - related party, net of allowance of $0 and $0 | 10,836 | 6,608 |
| Contract assets | 3,872 | 806 |
| Contract assets - related party | 33,679 | 36,638 |
| Inventories | 109,021 | 111,880 |
| Prepaid expenses and other current assets | 38,095 | 40,146 |
| Total current assets | 243,661 | 306,361 |
| Property, plant and equipment, net | 189,645 | 182,224 |
| Restricted cash, noncurrent | 6,135 | 6,090 |
| Recoverable taxes from Brazilian government entities | 30,189 | 29,472 |
| Right-of-use assets under financing leases, net | 147 | 152 |
| Right-of-use assets under operating leases, net | 100,721 | 97,216 |
| Goodwill | 50,456 | 142,575 |
| Intangible assets, net | 45,063 | 46,938 |
| Other assets | 13,662 | 13,904 |
| Total assets | 679,679 | 824,932 |
| Current liabilities: | ||
| Accounts payable | 200,067 | 190,486 |
| Accrued and other current liabilities | 81,068 | 73,565 |
| Financing lease liabilities | 14 | 13 |
| Operating lease liabilities | 2,484 | 2,255 |
| Contract liabilities | 33 | 26 |
| Debt, current portion | 1,968 | 1,916 |
| Related party debt, current portion | 185,160 | 118,886 |
| Total current liabilities | 470,794 | 387,147 |
| Long-term debt, net of current portion | 675,855 | 674,891 |
| Related party debt, net of current portion | 77,962 | 97,350 |
| Financing lease liabilities, net of current portion | 44 | 48 |
| Operating lease liabilities, net of current portion | 90,986 | 86,195 |
| Derivative liabilities | 4,140 | 5,403 |
| Acquisition-related contingent consideration | 2,241 | 34,555 |
| Other noncurrent liabilities | 5,725 | 7,053 |
| Total liabilities | 1,327,747 | 1,292,642 |
| Commitments and contingencies | ||
| Mezzanine equity: | ||
| Contingently redeemable common stock | 0 | 5,000 |
| Contingently redeemable noncontrolling interest | 26,058 | 28,892 |
| Stockholders’ (deficit) equity: | ||
| Common stock - $0.0001 par value, 550,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 368,524,240 and 364,745,266 shares issued and outstanding as of March 31, 2023 and December 31, 2022 | 37 | 36 |
| Additional paid-in capital | 2,465,802 | 2,455,567 |
| Accumulated other comprehensive loss | (56,682) | (64,114) |
| Accumulated deficit | (3,073,520) | (2,880,178) |
| Total Amyris, Inc. stockholders’ (deficit) equity | (664,363) | (488,689) |
| Noncontrolling interest | (9,763) | (12,913) |
| Total stockholders' (deficit) equity | (674,126) | (501,602) |
| Total liabilities, mezzanine equity and stockholders' (deficit) equity | $ 679,679 | $ 824,932 |
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.